Study of Benzoyl Peroxide Cream for Mild to Moderate Acne Vulgaris

NCT ID: NCT00558831

Last Updated: 2017-09-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 11 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-10-31
• Study Completion Date: 2008-01-31

Brief Summary

The purpose of this study is to compare the efficacy of a benzoyl peroxide 2.5% cream formulation plus a moisturizing lotion versus benzoyl peroxide 2.5% cream alone for the treatment of acne vulgaris.

Detailed Description

The purpose of this study is to compare the safety and efficacy of a benzoyl peroxide 2.5% cream formulation plus a moisturizing lotion versus benzoyl peroxide 2.5% cream alone for mild to moderate acne vulgaris.

Conditions

Acne Vulgaris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Benzoyl Peroxide

Benzoyl Peroxide (BP) 2.5%

Group Type: ACTIVE_COMPARATOR

Benzoyl Peroxide

Intervention Type: DRUG

Benzoyl Peroxide 2.5%

Benzoyl Peroxide plus moisturizing lotion

Benzyol Peroxide 2.5% plus moisturizing lotion

Group Type: ACTIVE_COMPARATOR

Benzoyl Peroxide

Intervention Type: DRUG

Benzoyl Peroxide 2.5%

Moisturizing Lotion

Intervention Type: DRUG

Interventions

Benzoyl Peroxide

Benzoyl Peroxide 2.5%

Intervention Type: DRUG

Moisturizing Lotion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Healthy male or female subjects who are 18 to 35 years of age.

2. Subjects are in good health and are free of any other facial skin disorders that may interfere with acne study assessments.

3. Subjects have the willingness and ability to understand and provide informed assent/consent to participate in the study and are able to communicate with the investigator. Subjects are willing and able to follow all study directions and to commit to all follow-up visits for the duration of the study. In addition, subjects must be willing to accept the restrictions of the study.

4. A minimum of 2 but no more than 30 inflammatory lesions (papules and pustules), relatively symmetrical in appearance on both sides of the face and a minimum of 2 but not more than 100 non-inflammatory lesions (open comedones and closed comedones) relatively symmetrical in appearance on both sides of the face.

5. Ongoing oral medications (other than those specifically for acne) are acceptable provided subjects are on a stable regimen throughout the study and provided the medications are determined likely to not interfere with study assessments.

6. Subjects will not use medicated cosmetics and/or soaps (including soaps containing antibacterial agents such as benzoyl peroxide, keratolytic agents such as salicylic acid, skin fresheners/astringents or aftershave lotions) for the duration of the study.

7. Subjects who agree not use any other acne treatment (including prescription and non-prescription medications) on the test site for the duration of the study.

8. Subjects who agree not to change facial cosmetic products during the study.

9. Subjects who agree to only use sunscreen/sunblock agents that are labeled as non-comedogenic.

Exclusion Criteria

1. Subjects or parents of subjects who are unable to understand the protocol or to give informed consent/assent.

2. Subjects with mental illness.

3. Subjects with no inflammatory acne.

4. Subjects with any acne cysts or nodules.

5. Subjects with acne conglobata, acne fulminans, secondary acne (e.g. Chloracne, drug-induced acne), or any acne requiring systemic treatment.

6. Subjects with excessive facial hair that may interfere with study assessments.

7. Subjects with other facial skin disorders that may interfere with study assessments.

8. Subjects with a history of skin cancer or actinic keratosis.

9. Subjects who have used tanning devices within one week prior to baseline study visit.

10. Subjects who have applied any topical products (e.g. emollients, sunscreens) or any cosmetics to the face at least one hour prior to study assessments.

11. Use of hormonal oral contraceptives for acne control or for less than 6 months prior to study baseline.

12. Subjects with known allergies, a history of, or sensitive to salicylic acid, benzoyl peroxide or any of the test article components.

13. Subjects using topical or systemic medication within 14 days before the study entry, which could interfere with study assessments. This includes but is not limited to the following: anti-inflammatory drugs (e.g. topical and systemic corticosteroids and systemic antihistamines), anti-acne drugs, topical and oral retinoids, topical antibacterial agents to the face, and any immunosuppressive drugs. Ongoing oral medications not expected to interfere with study assessments are allowed if the subject is on a stable regimen.

14. Subjects who are currently enrolled in another clinical investigation or have been enrolled in an acne trial within a period of 30 days prior to enrollment in this study.

15. Subjects who are pregnant or nursing.

16. Subjects who require electrolysis, waxing, or depilatories on the face during conduct of the study.

17. Subjects viewed by the investigator as not being able to complete the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 35 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Northwestern University

OTHER

Sponsor Role: lead

Responsible Party

Amy Paller

Principle Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Amy Paller, MD

Role: PRINCIPAL_INVESTIGATOR

Northwestern University

Locations

Northwestern University Department of Dermatology

Chicago, Illinois, United States

Countries

United States

Other Identifiers

STU1884

Identifier Type: -

Identifier Source: org_study_id